269 related articles for article (PubMed ID: 9256442)
1. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice.
Gnarra JR; Ward JM; Porter FD; Wagner JR; Devor DE; Grinberg A; Emmert-Buck MR; Westphal H; Klausner RD; Linehan WM
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9102-7. PubMed ID: 9256442
[TBL] [Abstract][Full Text] [Related]
2. Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis.
Kessler PM; Vasavada SP; Rackley RR; Stackhouse T; Duh FM; Latif F; Lerman MI; Zbar B; Williams BR
Mol Med; 1995 May; 1(4):457-66. PubMed ID: 8521303
[TBL] [Abstract][Full Text] [Related]
3. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.
Haase VH; Glickman JN; Socolovsky M; Jaenisch R
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1583-8. PubMed ID: 11171994
[TBL] [Abstract][Full Text] [Related]
4. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.
Richards FM; Schofield PN; Fleming S; Maher ER
Hum Mol Genet; 1996 May; 5(5):639-44. PubMed ID: 8733131
[TBL] [Abstract][Full Text] [Related]
5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
6. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
7. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
[TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus.
Walker C; Ahn YT; Everitt J; Yuan X
Mol Carcinog; 1996 Feb; 15(2):154-61. PubMed ID: 8599582
[TBL] [Abstract][Full Text] [Related]
9. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
Schoenfeld A; Davidowitz EJ; Burk RD
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8817-22. PubMed ID: 9671762
[TBL] [Abstract][Full Text] [Related]
10. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
Pause A; Lee S; Lonergan KM; Klausner RD
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):993-8. PubMed ID: 9448273
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
12. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
Gläsker S; Bender BU; Apel TW; van Velthoven V; Mulligan LM; Zentner J; Neumann HP
J Neurol Neurosurg Psychiatry; 2001 May; 70(5):644-8. PubMed ID: 11309459
[TBL] [Abstract][Full Text] [Related]
13. Von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization.
Nagashima Y; Miyagi Y; Udagawa K; Taki A; Misugi K; Sakai N; Kondo K; Kaneko S; Yao M; Shuin T
J Pathol; 1996 Nov; 180(3):271-4. PubMed ID: 8958804
[TBL] [Abstract][Full Text] [Related]
14. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila.
Adryan B; Decker HJ; Papas TS; Hsu T
Oncogene; 2000 Jun; 19(24):2803-11. PubMed ID: 10851083
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
[TBL] [Abstract][Full Text] [Related]
18. Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion.
Kuzmin I; Geil L; Ge H; Bengtsson U; Duh FM; Stanbridge EJ; Lerman MI
Oncogene; 1999 Oct; 18(41):5672-9. PubMed ID: 10523847
[TBL] [Abstract][Full Text] [Related]
19. Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis.
Hong SB; Furihata M; Baba M; Zbar B; Schmidt LS
Lab Invest; 2006 Jul; 86(7):664-75. PubMed ID: 16652107
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
